Michael G Harrington
Overview
Explore the profile of Michael G Harrington including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
4034
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fonteh A, Chiang A, Arakaki X, Edminster S, Harrington M
Front Neurosci
. 2021 Jan;
14:611393.
PMID: 33390893
Insight into lipids' roles in Alzheimer's disease (AD) pathophysiology is limited because brain membrane lipids have not been characterized in cognitively healthy (CH) individuals. Since age is a significant risk...
12.
Rochart R, Liu Q, Fonteh A, Harrington M, Arakaki X
Front Aging Neurosci
. 2020 Nov;
12:574214.
PMID: 33192465
Research shows that gamma activity changes in Alzheimer's disease (AD), revealing synaptic pathology and potential therapeutic applications. We aim to explore whether cognitive challenge combined with quantitative EEG (qEEG) can...
13.
Wei K, Tran T, Chang P, Malekie A, Chu K, Alhilali L, et al.
J Neuroimaging
. 2020 Nov;
31(1):186-191.
PMID: 33146918
Background And Purpose: Cirrhosis is associated with diffuse brain manganese deposition, which results in increased signal intensity (SI) in the brain on T1-weighted images, most often visualized in the globus...
14.
Arellanes I, Choe N, Solomon V, He X, Kavin B, Martinez A, et al.
EBioMedicine
. 2020 Jul;
59:102883.
PMID: 32690472
Background: Past clinical trials of docosahexaenoic Acid (DHA) supplements for the prevention of Alzheimer's disease (AD) dementia have used lower doses and have been largely negative. We hypothesized that larger...
15.
Asanad S, Fantini M, Sultan W, Nassisi M, Felix C, Wu J, et al.
PLoS One
. 2020 Jul;
15(7):e0236379.
PMID: 32663228
[This corrects the article DOI: 10.1371/journal.pone.0232785.].
16.
17.
Asanad S, Fantini M, Sultan W, Nassisi M, Felix C, Wu J, et al.
PLoS One
. 2020 May;
15(5):e0232785.
PMID: 32469871
Background: Alzheimer's disease (AD) pathology precedes symptoms and its detection can identify at-risk individuals who may benefit from early treatment. Since the retinal nerve fiber layer (RNFL) is depleted in...
18.
Montagne A, Nation D, Sagare A, Barisano G, Sweeney M, Chakhoyan A, et al.
Nature
. 2020 May;
581(7806):71-76.
PMID: 32376954
Vascular contributions to dementia and Alzheimer's disease are increasingly recognized. Recent studies have suggested that breakdown of the blood-brain barrier (BBB) is an early biomarker of human cognitive dysfunction, including...
19.
Sweeney M, Sagare A, Pachicano M, Harrington M, Joe E, Chui H, et al.
Alzheimers Dement
. 2020 Apr;
16(6):821-830.
PMID: 32301266
Introduction: Blood-brain barrier (BBB) breakdown and loss of brain capillary pericytes contributes to cognitive impairment. Pericytes express platelet-derived growth factor receptor-β (PDGFRβ) that regulates brain angiogenesis and blood vessel stability....
20.
Fonteh A, Cipolla M, Chiang A, Edminster S, Arakaki X, Harrington M
Front Physiol
. 2020 Mar;
11:83.
PMID: 32116789
Alzheimer's disease (AD) pathology is characterized by an early and prolonged decrease in the amyloid peptide (Aβ) levels concomitant with a later increase in phospho-tau concentrations in cerebrospinal fluid (CSF)....